Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edgewise TherapeuticsEWTX +3.18%28 PB Ratio is 10.41 as of Sep. 04, 2026. GuruFocus rates EWTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,216 Biotechnology companies, Edgewise Therapeutics ranks worse than 86.84% on this metric.
The historical rank and industry rank for Edgewise Therapeutics's PB Ratio or its related term are showing as below:
EWTX'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 10.4
Current: 10.4
During the past 7 years, Edgewise Therapeutics's highest PB Ratio was 10.40. The lowest was 0.00. And the median was 0.00.
EWTX's PB Ratio is ranked worse than 86.84% of 1216
companies
in the Biotechnology industry
Industry Median: 2.945
vs EWTX: 10.40
During the past 12 months, Edgewise Therapeutics's average Book Value Per Share Growth Rate was 1.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -3.60% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Edgewise Therapeutics was -3.60% per year. The lowest was -4.40% per year. And the median was -4.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Edgewise Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edgewise Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Edgewise Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Edgewise Therapeutics (EWTX) has a PB Ratio of 10.41 as of Sep. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Edgewise Therapeutics and its competitors. According to the industry distribution chart, Edgewise Therapeutics ranks #1056 out of 1216 companies in the Biotechnology industry, placing it in the top 86.8%.
Is Edgewise Therapeutics' PB Ratio too high?
Edgewise Therapeutics' current PB Ratio is 10.41. The Biotechnology industry median PB Ratio is 2.95. Edgewise Therapeutics' value of 10.41 is 253.5% above this industry median. Based on the distribution chart, Edgewise Therapeutics ranks #1056 out of 1216 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Edgewise Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Edgewise Therapeutics' PB Ratio compare to DYN and PBLS?
According to the Biotechnology industry distribution chart, Edgewise Therapeutics ranks #1056 out of 1216 companies for PB Ratio. This places Edgewise Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.95. Edgewise Therapeutics' value of 10.41 is 253.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,216 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edgewise Therapeutics's current PB Ratio of 10.41 is 253.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Edgewise Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edgewise Therapeutics's current PB Ratio is 10.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edgewise Therapeutics stock overvalued right now?
Edgewise Therapeutics (EWTX) has a current PB Ratio of 10.41. The current PB Ratio is 10.41 and 253.5% above the Biotechnology industry median of 2.95. Edgewise Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Edgewise Therapeutics (EWTX), the current PB Ratio is 10.41 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
28GF Score
Get the complete analysis for EWTX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EWTX has been successfully added to your 
